Go to content

Publications

Publications

337 publications

Enter search criteria

Fill in keyword(s) to narrow your search.

Period from
to

Enter a start and/or end date here, using the following format: DD-MM-YYYY.

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by: Date / Relevance

GVS assessment of Brimonidine Stulln 2mg/ml eye drop solution for decrease of increased intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension

Zorginstituut Nederland has completed its assessment whether Brimonidine Stulln 2mg/ml eye drop solution, single-use packaging is ...

Report | 24-02-2021

GVS assessment of formoterol/ glycopyrronium/ budesonide (Trixeo® aerosphere)

Zorginstituut Nederland has completed its assessment whether the product formoterol/glycopyrronium/budesonide (Trixeo® ...

Report | 22-02-2021

GVS assessment of sodium zirconium cyclosilicate (Lokelma®) for the treatment of hyperkalemia

Zorginstituut Nederland has completed its assessment whether sodium zirconium cyclosilicate (Lokelma®) is interchangeable with a ...

Report | 12-02-2021

Package advice multiple myeloma

Several combination therapies that are used to treat multiple myelomain are placed in the lock procedure for expensive medicinal ...

Report | 11-02-2021

GVS assessment of opicapone (Ongentys®) for the treatment of Parkinson's disease

Zorginstituut Nederland has completed its assessment whether opicapone (Ongentys®) is interchangeable with a product that has ...

Report | 03-02-2021

GVS assessment of givosiran (Givlaari®) for the treatment of acute hepatic porphyria

Zorginstituut Nederland has completed its assessment whether givosiran (Givlaari®) is interchangeable with a product that has ...

Report | 02-02-2021

GVS assessment oxybutynin intravesical solution (Vesolox®)

Zorginstituut Nederland has completed its assessment whether oxybutynin intravesical solution (Vesolox®) 1mg/ml is ...

Report | 18-01-2021

GVS advice mexiletine (Namuscla®)

Zorginstituut Nederland has completed its assessment whether the product mexiletine (Namuscla®) is interchangeable with another ...

Report | 13-01-2021

Advice on a potential candidate for conditional inclusion of rhPTH 1-84 (Natpar®) in chronic hypoparathyroidism

Zorginstituut Nederland recommends the minister of Medical Care that rhPTH 1-84 (Natpar®) be designated as a potential candidate ...

Letter | 21-12-2020

GVS advice concerning romosozumab (Evenity®) for the treatment of severe osteoporosis

Zorginstituut Nederland has completed its assessment whether romosozumab (Evenity®) is interchangeable with a product that is ...

Report | 16-12-2020

Go to